EBITDA PerformanceA 15% beat on adj. EBITDA as the Q2 margin surprises positively with 2.6%, coming out above the full year target corridor of 2.0-2.5%.
Financial TargetsManagement confirmed FY25 targets for all KPIs, suggesting an even stronger Q4.
Marketing InitiativesFollowing the lifting of the Rx bonus ban in Germany, increased marketing campaigns are expected to drive Rx sales in Q3 and beyond.
Sales GrowthRx sales improved again to €12m QoQ after just €6m in prior quarter.